Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo

Journal of Bone and Mineral Research

Volumn 12, Issue 9, 1997, Pages 1396-1406

  Votta, Bartholomew J ^a   Levy, Mark A ^a   Badger, Alison ^a   Bradbeer, Jeremy ^a   Dodds, Robert A ^a   James, Ian E ^a   Thompson, Scott ^a   Bossard, Mary J ^a   Carr, Thomas ^a   Connor, Janice R ^a   Tomaszek, Thaddeus A ^a   Szewczuk, Lawrence ^a   Drake, Fred H ^a   Veber, Daniel F ^a   Gowen, Maxine ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE; CATHEPSIN; CATHEPSIN K; CATHEPSIN K INHIBITOR; CYSTEINE PROTEINASE INHIBITOR; PAPAIN; PARATHYROID HORMONE[1-34]; POLYPEPTIDE; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; CATTLE; CONTROLLED STUDY; FETUS; HUMAN; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LONG BONE; MALE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROIDECTOMY; RAT; RHEUMATOID ARTHRITIS;

ALDEHYDES; ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE RESORPTION; CALCIUM; CATHEPSINS; CATTLE; ENZYME INHIBITORS; FEMALE; HUMANS; OLIGOPEPTIDES; PARATHYROID HORMONE; PARATHYROIDECTOMY; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RNA, MESSENGER; THYROIDECTOMY; TUMOR CELLS, CULTURED;

EID: 0030869303     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1997.12.9.1396     Document Type: Article

References (40)

1. Maciewicz RA, Etherington DJ 1988 A comparison of four cathepsins (B, L, N and S) with collagenolytic activity from rabbit spleen. Biochem J 256:433-440.
2. Delaisse J-M, Eeckhout Y, Vaes G 1984 In vivo and in vitro evidence for the involvement of cysteine-proteinase in bone resorption. Biochem Biophys Res Commun 125:441-447.
3. Lerner UH, Grubb A 1992 Human cystatin C, a cysteine proteinase inhibitor, inhibits bone resorption in vitro stimulated by parathyroid hormone and parathyroid hormone-related peptide of malignancy. J Bone Miner Res 7:433-439.
4. Delaisse JM, Boyde A, Maconnachie E, Ali NN, Sear CHJ, Eeckhout Y, Vaes G, Jones SJ 1987 The effects of inhibitors of cysteine-proteinases and collagenase on the resorptive activity of isolated osteoclasts. Bone 8:305-313.
5. Hill PA, Buttle DJ, Jones SJ, Boyde A, Murata M, Reynolds JJ, Meikle MC 1994 Inhibition of bone resorption by selective inactivators of cysteine proteinases. J Cell Biochem 56: 118-130.
6. Debari K, Sasaki N, Rifkin BR 1995 An ultrastructural evaluation of the effects of cysteine-proteinase inhibitors on osteoclastic resorptive functions. Calcif Tissue Int 56:566-570.
7. Bossard MJ, Tomaszek TA, Thompson SK, Amegadzie BY, Hanning CR, Jones C, Kurdyla JT, McNulty DE, Drake FH, Gowen M, Levy MA 1996 Proteolytic activity of human osteoclast cathepsin K: Expression, purification, activation, and substrate identification. J Biol Chem 271:12517-12524.
8. Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Rieman D, Barthlow R, Hastings G, Gowen M 1996 Cathepsin K, but not cathepsins B, L, S, is abundantly expressed in human osteoclasts. J Biol Chem 271:12511-12516.
9. Tezuka K-I, Tezuka Y, Maejima A, Sato T, Nemoto K, Kamioka H, Hakeda Y, Kumegawa M 1994 Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J Biol Chem 269:1106-1109.
10. Shi G-P, Chapman HA, Bhairi SM, DcLeeuw C, Reddy VY, Weiss SJ 1995 Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2. FEBS Lett 357:129-134.
11. Bromme D, Okamoto K 1995 Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol Chem Hoppe-Seyler 376:379-384.
12. Li YP, Alexander M, Wucherpfennig AL, Yelick P, Chen W, Stashenko P 1995 Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas. J Bone Miner Res 10:1197-1202.
13. Inaoka T, Bilbe G, Ishibashi O, Tezuka K-I, Kamegawa M, Kokubo T 1995 Molecular cloning of human cDNA for cathepsin K: Novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun 206:89-96.
14. Bromme D, Okamoto K, Wang BB, Biroc S 1996 Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts: Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem 271:2126-2132.
15. Gelb BD, Shi G-P, Chapman HA, Desnick RJ 1996 Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236-1238.
16. Goel O, Krolls U, Stier M, Keston S 1989 N-tert-butoxycarbonyl-L-leucinal. Org Synth 67:69-75.
17. McConnell RM, Barnes GE, Hoyng CF, Gunn JM 1990 New leupeptin analogues: Synthesis and inhibition data. J Med Chem 33:86-93.
18. Zhao B, Janson CA, Amegadzie BY, D'Alessio K, Griffin C, Hanning CR, Jones C, Kurdyla J, McQueney M, Qui X, Smith WW, Abdel-Meguid SS 1997 Crystal structure of human osteoclast cathepsin K complex with E-64. Nature Struct Biol 4:109-111.
19. Cleland WW 1979 The statistical analysis of enzyme kinetic data. Adv Enzymol Relat Areas Mol Biol 29:1-32.
20. Dixon M 1953 The determination of enzyme inhibitor constants. Biochem J 55:170-171.
21. Morrison JF, Walsh CT 1988 The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61:201-301.
22. Muller-Steffner HM, Malver O, Hosie L, Oppenheimer NJ, Schuber F 1992 Slow-binding inhibition of NAD+ glycohydrolase by arabino analogues of beta-NAD. J Biol Chem 267: 9606-9611.
23. Brady K, Abeles RH 1990 Inhibition of chymotrypsin by peptidyl trifluoromethyl ketones: determinants of slow-binding kinetics. Biochemistry 29:7608-7617.
24. Zeller R, Rodgers M 1990 In situ hybridization to cellular RNA. In: Ausable RM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K (eds.) Current Protocols in Molecular Biology. John Wiley & Sons, Green Publishing Associates, New York, NY, U.S.A., pp. 14.2.1-14.3.11.
25. Dodds RA, Connor JR, James IE, Lee-Rykaczewski E, Appelbaum E, Dul E, Gowen M 1995 Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: An in vitro and ex vivo study of remodeling bone. J Bone Miner Res 10:1666-1680.
26. Raisz LG 1965 Bone resorption in tissue culture: Factors influencing the response to parathyroid hormone. J Clin Invest 44:103-116.
27. Stern PH, Raisz LG 1979 Organ cultures of bone. In Skeletal Researcher: An experimental approach. Academic Press, New York, NY, U.S.A., pp. 21-29.
28. Votta BJ, Bertolini DR 1994 Cytokine suppressive antiinflammatory compounds inhibit bone resorption in vitro. Bone 15:533-538.
29. James IE, Dodds RA, Olivera DL, Nuttall ME, Lackman RD, Gowen M 1996 The ability of human osteoclastoma-derived stromal cells to form mineralized nodules in vitro is correlated with their ability to form bone in vivo. J Bone Miner Res 11:1453-1460.
30. Foged NT, Delaisse J-M, Hou P, Lou H, Sato T, Winding B, Bonde M 1996 Quantification of the collagenolytic activity of isolated osteoclasts by Enzyme-linked immunosorbent assay. J Bone Miner Res 11:226-237.
31. Thompson DD, Seedor JG, Fisher JE, Rosenblatt M, Rodan GA 1988 Direct action of the parathyroid hormone-like human hypercalcemic factor on bone. Proc Natl Acad Sci USA 85:5673-5677.
32. Hart KA, Potts W, Bowyer J, Slynn G, Elston P, Vernon W, Tucker D, Tolley K, Johnstone D 1996 Transgenic mice lacking cathepsin L activity. J Bone Miner Res 11 (Suppl 1):S366 (abstract).
33. Greenspan A 1991 Sclerosing bone dysplasias - A target-site approach. Skeletal Radiol 20:561-583.
34. Sarnsethsiri P, Hitt OK, Eyring EJ, Frost HM 1971 Tetracycline-based study of bone dynamics in pycnodysostosis. Clin Orthoped Rel Res 74:301-312.
35. Cabrejas ML, Fromm GA, Roca JF, Mendez MA, Bur GE, Ferreyra ME, Demarchi C, Schurman L 1976 Pycnodysostosis: Some aspects concerning kinetics of calcium metabolism and bone pathology. Am J Med Sci 271:215-220.
36. Meredith SC, Simon MA, Laros GS, Jackson MA 1978 Pycnodysostosis: A clinical, pathological, and ultramicroscopic study of a case. J. Bone Joint Surg 60:1122-1127.
37. Elmore SM, Nance WE, McGee BJ, Montmollin ME, Engel E 1966 Pycnodysostosis, with a familial chromosome anomaly. Am J Med 40:273-282.
38. Schultz RM, Varma-Nelson P, Ortiz R, Kozlowski KA, Orawski AT, Pagast P, Frankfater A 1989 Active and inactive forms of the transition-state analog protease inhibitor leupeptin: Explanation of the observed slow binding of leupeptin to cathepsin B and papain. J Biol Chem 264:1497-1507.
39. Fisher JE, Caulfield MP, Sato M, Quartuccio HA, Gould RJ, Garsky VM, Rodan GA, Rosenblatt M 1993 Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein. Endocrinology 132:1411-1413.
40. Crippes BA, Engleman VW, Settle SL, Delarco J, Ornberg RL, Helfrich MH, Horton MA, Nickols GA 1996 Antibody to β3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Endocrinology 137:918-924.